NASDAQ:APVO - Aptevo Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.79 0.00 (0.00 %)
(As of 05/19/2019 02:18 AM ET)
Previous Close$0.7891
Today's Range$0.7650 - $0.8095
52-Week Range$0.67 - $6.09
Volume417,313 shs
Average Volume478,124 shs
Market Capitalization$35.58 million
P/E RatioN/A
Dividend YieldN/A
Beta2.64
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its investigational stage product candidates comprise APVO436, a bispecific immunotherapeutic protein that is in Phase 1/1b clinical trial for acute myeloid leukemia and high-grade myelodysplastic syndrome; APVO210, an anti-inflammatory molecule that is in pre-clinical development stage for the treatment of autoimmune and inflammatory diseases; ALG.APV-527, a bispecific antibody to target T cells; ROR1 Bispecific, a proof-of-concept bispecific candidate that is in preclinical development; and other pre-clinical development stage therapeutics focused on immuno-oncology. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Receive APVO News and Ratings via Email

Sign-up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:APVO
CUSIPN/A
Phone206-838-0500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$23.07 million
Book Value$0.87 per share

Profitability

Net Income$-53,690,000.00
Net Margins-199.24%

Miscellaneous

Employees118
Market Cap$35.58 million
Next Earnings Date8/8/2019 (Estimated)
OptionableOptionable

Aptevo Therapeutics (NASDAQ:APVO) Frequently Asked Questions

What is Aptevo Therapeutics' stock symbol?

Aptevo Therapeutics trades on the NASDAQ under the ticker symbol "APVO."

How were Aptevo Therapeutics' earnings last quarter?

Aptevo Therapeutics Inc (NASDAQ:APVO) posted its quarterly earnings results on Thursday, May, 9th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.44). The biotechnology company had revenue of $7.02 million for the quarter, compared to analyst estimates of $6.30 million. Aptevo Therapeutics had a negative net margin of 199.24% and a negative return on equity of 122.33%. View Aptevo Therapeutics' Earnings History.

When is Aptevo Therapeutics' next earnings date?

Aptevo Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, August 8th 2019. View Earnings Estimates for Aptevo Therapeutics.

What price target have analysts set for APVO?

3 brokers have issued 1-year price objectives for Aptevo Therapeutics' stock. Their forecasts range from $4.50 to $14.00. On average, they anticipate Aptevo Therapeutics' share price to reach $10.1667 in the next twelve months. This suggests a possible upside of 1,188.4% from the stock's current price. View Analyst Price Targets for Aptevo Therapeutics.

What is the consensus analysts' recommendation for Aptevo Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptevo Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aptevo Therapeutics.

Has Aptevo Therapeutics been receiving favorable news coverage?

Press coverage about APVO stock has been trending negative recently, InfoTrie reports. The research firm rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aptevo Therapeutics earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next few days.

Who are some of Aptevo Therapeutics' key competitors?

What other stocks do shareholders of Aptevo Therapeutics own?

Who are Aptevo Therapeutics' key executives?

Aptevo Therapeutics' management team includes the folowing people:
  • Mr. Marvin L. White, Pres, CEO & Director (Age 57)
  • Mr. Jeffrey G. Lamothe, Sr. VP, CFO & Treasurer (Age 53)
  • Dr. Scott C. Stromatt, Sr. VP of Clinical Devel. & Medical Affairs and Chief Medical Officer (Age 61)
  • Mr. Randy Joe Maddux, Sr. VP of Operations & Chief Manufacturing Officer (Age 58)
  • Dr. Jane A. Gross, Sr. VP & Chief Scientific Officer (Age 62)

Who are Aptevo Therapeutics' major shareholders?

Aptevo Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (3.07%), Renaissance Technologies LLC (2.75%), Park West Asset Management LLC (2.22%), Acadian Asset Management LLC (0.36%) and Marshall Wace LLP (0.08%). Company insiders that own Aptevo Therapeutics stock include Marvin L White and Randy Joe Maddux. View Institutional Ownership Trends for Aptevo Therapeutics.

Which institutional investors are selling Aptevo Therapeutics stock?

APVO stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Renaissance Technologies LLC and Dimensional Fund Advisors LP. View Insider Buying and Selling for Aptevo Therapeutics.

Which institutional investors are buying Aptevo Therapeutics stock?

APVO stock was purchased by a variety of institutional investors in the last quarter, including Park West Asset Management LLC and Marshall Wace LLP. Company insiders that have bought Aptevo Therapeutics stock in the last two years include Marvin L White and Randy Joe Maddux. View Insider Buying and Selling for Aptevo Therapeutics.

How do I buy shares of Aptevo Therapeutics?

Shares of APVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aptevo Therapeutics' stock price today?

One share of APVO stock can currently be purchased for approximately $0.7891.

How big of a company is Aptevo Therapeutics?

Aptevo Therapeutics has a market capitalization of $35.58 million and generates $23.07 million in revenue each year. The biotechnology company earns $-53,690,000.00 in net income (profit) each year or ($2.39) on an earnings per share basis. Aptevo Therapeutics employs 118 workers across the globe.

What is Aptevo Therapeutics' official website?

The official website for Aptevo Therapeutics is http://www.aptevotherapeutics.com.

How can I contact Aptevo Therapeutics?

Aptevo Therapeutics' mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The biotechnology company can be reached via phone at 206-838-0500 or via email at [email protected]


MarketBeat Community Rating for Aptevo Therapeutics (NASDAQ APVO)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  121 (Vote Outperform)
Underperform Votes:  136 (Vote Underperform)
Total Votes:  257
MarketBeat's community ratings are surveys of what our community members think about Aptevo Therapeutics and other stocks. Vote "Outperform" if you believe APVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/19/2019 by MarketBeat.com Staff

Featured Article: What is the LIBOR?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel